Next Article in Journal
Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
Previous Article in Journal
Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors
Review

Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation

1
Princess Máxima Center for Pediatric Oncology, Utrecht University, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands
2
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1974; https://doi.org/10.3390/cancers12071974
Received: 19 June 2020 / Revised: 10 July 2020 / Accepted: 16 July 2020 / Published: 20 July 2020
Allogeneic (allo) hematopoietic cell transplantation (HCT) is the only curative treatment option for patients suffering from chemotherapy-refractory or relapsed hematological malignancies. The occurrence of morbidity and mortality after allo-HCT is still high. This is partly correlated with the immunological recovery of the T cell subsets, of which the dynamics and relations to complications are still poorly understood. Detailed information on T cell subset recovery is crucial to provide tools for better prediction and modulation of adverse events. Here, we review the current knowledge regarding CD4+ and CD8+ T cells, γδ T cells, iNKT cells, Treg cells, MAIT cells and naive and memory T cell reconstitution, as well as their relations to outcome, considering different cell sources and immunosuppressive therapies. We conclude that the T cell subsets reconstitute in different ways and are associated with distinct adverse and beneficial events; however, adequate reconstitution of all the subsets is associated with better overall survival. Although the exact mechanisms involved in the reconstitution of each T cell subset and their associations with allo-HCT outcome need to be further elucidated, the data and suggestions presented here point towards the development of individualized approaches to improve their reconstitution. This includes the modulation of immunotherapeutic interventions based on more detailed immune monitoring, aiming to improve overall survival changes. View Full-Text
Keywords: allogeneic hematopoietic cell transplantation; hematological malignancies; immune reconstitution; T cell subsets; serotherapy; conditioning; immunosuppressive therapies; biomarkers allogeneic hematopoietic cell transplantation; hematological malignancies; immune reconstitution; T cell subsets; serotherapy; conditioning; immunosuppressive therapies; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Dekker, L.; de Koning, C.; Lindemans, C.; Nierkens, S. Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation. Cancers 2020, 12, 1974. https://doi.org/10.3390/cancers12071974

AMA Style

Dekker L, de Koning C, Lindemans C, Nierkens S. Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation. Cancers. 2020; 12(7):1974. https://doi.org/10.3390/cancers12071974

Chicago/Turabian Style

Dekker, Linde, Coco de Koning, Caroline Lindemans, and Stefan Nierkens. 2020. "Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation" Cancers 12, no. 7: 1974. https://doi.org/10.3390/cancers12071974

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop